Título : |
Single daily dose amikacin in paediatric patients with severe gram-negative infections |
Tipo de documento : |
documento electrónico |
Autores : |
David Andrés Espinal Botero, ; Hugo Trujillo Soto, |
Fecha de publicación : |
1991 |
Títulos uniformes : |
Journal of Antimicrobial Chemotherapy
|
Idioma : |
Inglés (eng) |
Resumen : |
Twenty-five children with serious Gram-negative infections were treated in a prospective study with amikacin 20 mg/kg administered in a single daily dose as a 30 min iv infusion for 4 to 12 days. In nine cases the amikacin was combined with β-lactam antibiotics. Escherichia coli were the most frequent bacteria isolated followed by K. pneumoniae, Providencia and Enterobacter spp. and Pseudomonas aeruginosa with MICs ranging from 1 to 16 mg/l. Mean (±S.D.) peak and trough concentrations of days 1 and 4 of therapy ranged from 49+13·5 to 53·6±13·4 mg/l and 6±1·4 to 7·7+4·1 mg/l respectively. All patients were clinically and bacteriologically cured. No significant adverse reactions were observed. The results suggest that administration of a single daily dose of 20 mg/kg amikacin should be considered practical and safe in children. Further studies are needed. |
Mención de responsabilidad : |
Hugo Trujillo, Jaime Robledo, Carlos Robledo, David Espinal, Gloria Garces, Jorje Mejia, Carlos Restrepo, Felipe Restrepo, Gloria Isabel Mejia de Rodriguez, Marta Claudia Tamayo de Guitierrez |
Referencia : |
J Antimicrob Chemother. 1991 May;27 Suppl C:141-7 |
DOI (Digital Object Identifier) : |
10.1093/jac/27.suppl_c.141 |
PMID : |
1856143 |
En línea : |
https://academic.oup.com/jac/article-abstract/27/suppl_C/141/660223 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4359 |
Single daily dose amikacin in paediatric patients with severe gram-negative infections [documento electrónico] / David Andrés Espinal Botero, ; Hugo Trujillo Soto, . - 1991. Obra : Journal of Antimicrobial ChemotherapyIdioma : Inglés ( eng) Resumen : |
Twenty-five children with serious Gram-negative infections were treated in a prospective study with amikacin 20 mg/kg administered in a single daily dose as a 30 min iv infusion for 4 to 12 days. In nine cases the amikacin was combined with β-lactam antibiotics. Escherichia coli were the most frequent bacteria isolated followed by K. pneumoniae, Providencia and Enterobacter spp. and Pseudomonas aeruginosa with MICs ranging from 1 to 16 mg/l. Mean (±S.D.) peak and trough concentrations of days 1 and 4 of therapy ranged from 49+13·5 to 53·6±13·4 mg/l and 6±1·4 to 7·7+4·1 mg/l respectively. All patients were clinically and bacteriologically cured. No significant adverse reactions were observed. The results suggest that administration of a single daily dose of 20 mg/kg amikacin should be considered practical and safe in children. Further studies are needed. |
Mención de responsabilidad : |
Hugo Trujillo, Jaime Robledo, Carlos Robledo, David Espinal, Gloria Garces, Jorje Mejia, Carlos Restrepo, Felipe Restrepo, Gloria Isabel Mejia de Rodriguez, Marta Claudia Tamayo de Guitierrez |
Referencia : |
J Antimicrob Chemother. 1991 May;27 Suppl C:141-7 |
DOI (Digital Object Identifier) : |
10.1093/jac/27.suppl_c.141 |
PMID : |
1856143 |
En línea : |
https://academic.oup.com/jac/article-abstract/27/suppl_C/141/660223 |
Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4359 |
| |